FDA sets limits for lead in many baby foods as California disclosure law takes effect
The FDA has set maximum levels for lead in baby food. A new California law requires baby food makers selling products in the ...
Pizza Recall Update As FDA Sets Risk Level Over Plastic Contamination
The recalled "Connie's Thin Crust Cheese Pizza" was issued a Class II risk level by the FDA, the second-most severe risk ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
FDA sets limits on lead in some baby foods
But consumer advocates say the Food and Drug Administration's new guidance on lead limit in baby food doesn't go far enough.
Healio1h
FDA grants priority review to nipocalimab for myasthenia gravis
The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...
STAT5h
Patrizia Cavazzoni, head of FDA’s drug center, to leave the agency
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
BioPharma Dive2h
Patrizia Cavazzoni, key FDA official, to leave agency
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
STAT3h
In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
FiercePharma5h
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
FiercePharma6h
FDA cancels adcomm in 'positive' sign for Exelixis’ Cabometyx bid in neuroendocrine tumors: analyst
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
4D Molecular, FDA agree on phase 3 design for DME candidate
D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...
Healio7h
Diversity in pulse oximeter clearance summaries increases after 2013 FDA guidance
Following the FDA’s release of a guidance requesting more diversity in pulse oximeter testing, the number of clearance ...